Signal from the log
Caspian Therapeutics
50 M$ · United States · Biotech
Société créée par Kura Oncology pour sortir de son portefeuille l'inhibiteur de ménine KO-7246 et le porter vers le diabète plutôt que vers le cancer. Le pari est de restaurer le nombre et la fonction des cellules bêta, donc de modifier la maladie au lieu d'en corriger la glycémie. Kura garde environ la moitié du capital.
Verified
Announced on , logged by the watch of 9 September 2026.
- Operation
- Funding round
- Announced amount
- 50 M$
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by BVF Partners , with JDRF T1D Fund , Invus , Montanova , Eli Lilly and Company , Kura Oncology
What is missing before publishing
- The stage of the round is not disclosed. A letter is never inferred from an amount or a track record.
Provenance
Source edgar,endpoints
Logged on 9 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.